JPM
59
6
LH
33
3
COP
36
2
NTAP
58
3
ES
12
3
HSIC
42
2
M
40
3
PYPL
49
4
BAX
38
2
NVDA
52
5
DD
44
2
HPE
48
2
USB
50
3
DVA
62
5
DUK
49
4
VIX
41
-11
O
26
16
DGX
28
4
LEN
21
3
ADP
57
2
JPM
59
6
LH
33
3
COP
36
2
NTAP
58
3
ES
12
3
HSIC
42
2
M
40
3
PYPL
49
4
BAX
38
2
NVDA
52
5
DD
44
2
HPE
48
2
USB
50
3
DVA
62
5
DUK
49
4
VIX
41
-11
O
26
16
DGX
28
4
LEN
21
3
ADP
57
2
Financhill
Back

Capricor Therapeutics 10K Form

Sell
44

CAPR
Capricor Therapeutics

Last Price:
$13.10
Seasonality Move:
42.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CAPR News And Ratings

See the #1 stock for the next 7 days that we like better than CAPR

CAPR Financial Statistics

Sales & Book Value

Annual Sales: $25.2M
Cash Flow: $-11.7M
Price / Cash Flow: 0
Annual Sales: $1.69
Price / Book: 8.71

Profitability

EPS (TTM): -1.02000
Net Income (TTM): $-34.1M
Gross Margin: $500K
Return on Equity: -143.31%
Return on Assets: -61.67%

Capricor Therapeutics Earnings Forecast

Key Capricor Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for CAPR have been equal to 49.11% of Gross Profit Margin.
  • The Research & Development expenses have been 144.76% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CAPR is -88.52% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 12 years.

Capricor Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CAPR
CUSIP: 14070B
Website: capricor.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.19
Quick Ratio: 4.17

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CAPR Technical Analysis vs Fundamental Analysis

Sell
44
Capricor Therapeutics (CAPR) is a Sell

Is Capricor Therapeutics a Buy or a Sell?